

Paper No. ____
Filed: July 30, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS IV LLC

Petitioner

v.

PHARMACYCLICS LLC

Patent Owner

Case IPR2015-01076
Patent No. 8,754,090

**PATENT OWNER'S MOTION FOR SANCTIONS PURSUANT TO
37 C.F.R. § 42.12**

Table of Contents

	Page
I. INTRODUCTION	1
II. RELIEF REQUESTED	2
III. REASONS FOR REQUESTED RELIEF	3
A. The Legislative History Shows <i>Inter Partes</i> Reviews Were Designed To Offer An Efficient, Cost-Effective Litigation Alternative	3
B. The Board Should Dismiss the Petition As A Sanction For Petitioner’s Abuse Of Process And Improper Use.....	6
1. The Board Should Adopt The Traditional Approach To Abuse Of Process And Improper Use.....	6
2. The Board Should Apply A “Reasonable Likelihood” Standard Of Proof In Adjudicating Motions For Sanctions For Abuse Of Process Or Improper Use	10
3. The Petitioner Is Improperly Using This Proceeding To Affect Pharmacyclics’s Stock Price, A Purpose For Which It Was Not Designed	11
IV. CONCLUSION.....	15

Table of Authorities

Page(s)

Cases

<i>Dassault Systemes, S.A. v. Childress</i> , No. 09-10534, 2014 WL 6865498 (E.D. Mich. Dec. 3, 2014).....	8
<i>Herman & Maclean v. Henderson</i> , 459 U.S. 375 (1983).....	10, 11
<i>In re Applications of High Plains Wireless, L.P.</i> , 15 F.C.C. Rcd. 4620 (2000).....	8
<i>Steadman v. SEC</i> , 450 U.S. 91 (1981).....	10, 11
<i>Vitronics Corp. v. Conceptronic, Inc.</i> , No. C-91-696-L, 1993 WL 300882 (D.N.H. Mar. 29, 1993).....	8
<i>Wenger Mfg., Inc. v. Coating Mach. Sys., Inc.</i> , No. 4-98-CV-90083, 1999 WL 33268173 (S.D. Iowa Sept. 30, 1999).....	8

Statutes

35 U.S.C. § 314(a)	10
35 U.S.C. § 316.....	1
5 U.S.C. § 556(d).....	11

Other Authorities

153 Cong. Rec. E774 (Apr. 18, 2007)	4
157 Cong. Rec. S5319-03 (Sept. 6, 2011).....	3
H.R. Rep. No. 112-98, pt 1 (June 1, 2011)	4
RESTATEMENT OF TORTS (2d.) § 682 (1979).....	7, 8
S. Rep. No. 110-259 (Jan. 24, 2008).....	4

Rules

FED. R. EVID. 404(b)(2).....	13
------------------------------	----

Regulations

37 C.F.R. § 42.1(b)	2, 8
37 C.F.R. § 42.12	2, 3
37 C.F.R. § 42.12(a)(7).....	9

PATENT OWNER'S UPDATED EXHIBIT LIST

Pharmacyclics Exhibit No.	DESCRIPTION
2001	FDA Press Release, "FDA Approves Imbruvica For Rare Blood Cancer" (Nov. 13, 2013), <i>available at</i> http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374761.htm
2002	Howard, O., "Mantle Cell Lymphoma." <i>Malignant Lymphomas</i> Ed. Grossbard, ML London: BC Decker Inc. 2002 135-51)
2003	Wang, M., et al., Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, 369 N. Eng. J. Med. 507 (2013)
2004	European Medicines Agency, "Assessment Report for Torisel" (August 25, 2009), <i>available at</i> http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000799/WC500039918.pdf
2005	Ohio State University Medical Center. "Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma." ScienceDaily (June 19, 2013) <i>available at</i> www.sciencedaily.com/releases/2013/06/130619195217.htm .
2006	Johnson & Johnson Press Release, "Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration" (Feb. 12, 2013), <i>available at</i> http://www.jnj.com/news/all/ibrutinib-receives-two-oncology-breakthrough-therapy-designations-from-us-food-and-drug-administration
2007	S. 3187 Prescription Drug User Fee Amendments of 2012
2008	Office Action, Non-Final Rejection (March 13, 2013), U.S. Patent App. No. 13/340,522
2009	Notice of Allowability (March 31, 2014), U.S. Patent App. No. 13/340,522
2010	Chang, B.Y., et al "Egress of CD191CD51 cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients" <i>Blood</i> , 122(14): 2412-2424
2011	Schlette, E., et al, "CD23 Expression in Mantle Cell Lymphoma: Clinicopathologic Features of 18 Cases" <i>Am J. Clin. Pathol.</i>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.